SPONSORED BY TD MEDIA LLC AND DISSEMINATED ON BEHALF OF MEDICUS PHARMA LTD.*

Good Morning Market Enthusiast,

For decades, the global standard for treating the most prevalent form of cancer has remained fundamentally unchanged: the scalpel. Every year, millions of patients undergo invasive surgical procedures that, while effective, often leave behind significant scarring, require extensive wound care, and can result in permanent disfigurement. In a world defined by rapid technological advancement, this reliance on traditional excision has long represented a massive gap in clinical innovation.

But the era of the blade may finally be meeting its match. Imagine a future where a simple, non-invasive patch could replace the surgeon’s knife, delivering precision therapy directly to the source of the disease without the systemic burden of traditional treatments. That future is no longer a distant possibility.

Introducing Medicus Pharma Ltd. (Nasdaq: MDCX), a clinical-stage biotech powerhouse that is currently disrupting the oncology landscape with a first-in-class pipeline designed to treat the world’s most common cancer… without surgery.

(1)

Today, March 26, 2026, marks the most significant milestone in the company's history. As Medicus Pharma Ltd. (Nasdaq: MDCX) prepares to host its comprehensive business update, the conversation has officially shifted from "anticipated potential" to "decision-grade evidence". (3)

The Breakthrough: 73% Clinical Clearance in Basal Cell Carcinoma (1)(2)(3)(4)

On March 5, 2026, Medicus Pharma Ltd. (Nasdaq: MDCX) announced positive topline results from its randomized, double-blind, placebo-controlled Phase 2 clinical study (SKNJCT-003). The study was specifically designed to evaluate the safety and clinical activity of a Doxorubicin Microneedle Array (D-MNA)—marketed as SkinJect™—as a non-invasive treatment for nodular basal cell carcinoma (BCC).

(7)

The results from the high-dose (200µg) cohort at Day 57 have sent shockwaves through the clinical community:
 

• 73% Clinical Clearance: Approximately three out of every four treated lesions achieved complete visual disappearance.
• 40% Histological Clearance: The complete elimination of tumor cells was confirmed via biopsy in 40% of the participants in this specific cohort.
• Clear Separation from Control: The active therapeutic arm demonstrated a sharp separation from the device-only (P-MNA) control group, which showed a 38% clinical clearance rate.
   

Management at Medicus Pharma Ltd. (Nasdaq: MDCX) has characterized these results as "decision-grade," providing the robust foundation required to move toward an End-of-Phase 2 (EOP2) meeting with the FDA in the first half of 2026.
 

The Science of Disruption: Beyond Traditional Methods (1)(2)(3)(4)
 

Basal cell carcinoma is the most common cancer in humans, with an estimated 3.6 million cases diagnosed annually in the United States alone. For many, the diagnosis means repeated trips to the dermatologist, wound care, and the psychological burden of disfigurement, especially for lesions appearing on the face or neck.
 

The SkinJect™ program from Medicus Pharma Ltd. (Nasdaq: MDCX) represents a fundamental shift toward localized, precision oncology. By utilizing a patented, dissolvable microneedle patch, the oncology candidate is delivered directly into the tumor tissue. This delivery mechanism offers several critical advantages:
 

• No Systemic Burden: The therapeutic agent remains localized at the tumor site, avoiding the debilitating side effects often associated with traditional chemotherapy, such as hair loss or nausea.
• Mechanical and Biological Disruption: The physical insertion of the microneedles produces localized micro-injury, which triggers the body’s natural wound-healing pathways and mechanically disrupts the tumor architecture.
• Localized Immune Activation: BCC is known to be a highly immunogenic tumor. The localized disruption caused by the microneedles—even in the device-only arm—can amplify the body’s own immune signaling to target and combat the malignancy.
   

This dual-action approach—combining the therapy effect with the device-mediated biological response—is exactly what drove the 73% clearance rate observed in the Phase 2 study for Medicus Pharma Ltd. (Nasdaq: MDCX).

The $8 Billion Pipeline: A Two-Front Strategy (1)(2)(3)(4)

While the SkinJect™ data is the primary catalyst today, it represents only half of an estimated $8 billion combined market opportunity for Medicus Pharma Ltd. (Nasdaq: MDCX). The second pillar of the company’s strategy is Teverelix®, a next-generation prostate cancer program.

Addressing the Cardiovascular Gap in Prostate Cancer More than 3.5 million men in the U.S. are living with prostate cancer, and cardiovascular disease remains the leading cause of non-cancer death in these patients. Current hormone therapies, specifically GnRH agonists, can cause a "testosterone flare" that has been linked to increased cardiovascular risk.

Teverelix® is a long-acting GnRH antagonist designed to eliminate this flare entirely.
 

• Rapid Suppression: Clinical observations show testosterone levels begin to drop within approximately two days.
• Dosing Interval: The program is designed for injections every six weeks, potentially improving patient compliance compared to monthly injections or daily oral options.
• FDA Milestone: On February 10, 2026, the FDA granted "study may proceed" clearance for a Phase 2b dose-optimization study in men with advanced prostate cancer.
   

With the advanced prostate cancer and acute urinary retention relapse (AURr) markets totaling nearly $6 billion, Teverelix® provides a significant second front in the clinical roadmap for Medicus Pharma Ltd. (Nasdaq: MDCX).

The Humanitarian Impact: Gorlin Syndrome (1)(2)(3)(4)

Beyond the broad BCC market, Medicus Pharma Ltd. (Nasdaq: MDCX) is aggressively pursuing a rare disease angle for SkinJect™. In October 2025, the company announced a collaboration with the Gorlin Syndrome Alliance to pursue an Expanded Access program with the FDA.

Patients with Gorlin Syndrome can develop dozens or even hundreds of BCC lesions over their lifetime. For these individuals, continuous surgical intervention is not just burdensome; it is often devastating. A non-invasive, repeatable patch treatment could fundamentally change their quality of life. From a regulatory standpoint, rare disease designations can lead to accelerated pathways, including Priority Review Vouchers, which have historically commanded significant value.

Strategic Alignment: The $14 Million Commitment  (1)(2)(3)(4)

One of the most notable aspects of the corporate narrative for Medicus Pharma Ltd. (Nasdaq: MDCX) is the level of internal conviction. CEO Dr. Raza Bokhari has disclosed that the leadership team has placed nearly $14 million of their own personal capital into the company.

This placement was made at $4.00 per share—a level significantly higher than where the equity has recently traded. This "skin in the game" aligns leadership directly with the clinical success of the pipeline and suggests a strong internal belief that the current market valuation does not fully reflect the value of the "decision-grade" Phase 2 data.

Today’s Critical Event: The Business Update Webcast (3)

The most important step for those following the Medicus Pharma Ltd. (Nasdaq: MDCX) narrative is joining today’s business update webcast. This call will feature a deep dive into the clinical results and the company's roadmap for the remainder of 2026.

Webcast Details:
 

• Date: Thursday, March 26, 2026
• Time: 11:30 a.m. Eastern Time
   

Why You Should Attend This session is not just a corporate update; it is a clinical review featuring Dr. Babar K. Rao, the Principal Investigator for the SKNJCT-003 study. Dr. Rao is a world-renowned academic dermatologist and Key Opinion Leader (KOL) with over 200 peer-reviewed publications.

During the call, Dr. Rao will provide:
 

1. Independent Investigator Perspective: A look at the real-world implications of 73% clinical clearance.
2. Tumor Response Mechanisms: An explanation of how the SkinJect™ platform triggers immune activation.
3. Future Clinical Trajectory: Insights into how this data supports the path toward a pivotal Phase 3 trial or potential strategic licensing.
    

The 2026 Catalyst Calendar (1)(2)(3)(4)(5)(6)(7)
 

With the Phase 2 data now officially part of the record, the next twelve months are expected to be the most active in the history of Medicus Pharma Ltd. (Nasdaq: MDCX):
 

• Q2 2026: Finalization of the Clinical Study Report (CSR).
• H1 2026: Planned End-of-Phase 2 Meeting with the FDA to finalize the registrational pathway.
• H1 2026: Initiation of the Teverelix® Phase 2b dose-optimization study.
• Ongoing 2026: Acceleration of strategic partnership and licensing discussions based on "decision-grade" data packages.
   

As the gap between the current valuation and the $27 analyst target continues to be a point of discussion, today's 11:30 a.m. ET webcast remains the most direct way to evaluate the momentum behind Medicus Pharma Ltd. (Nasdaq: MDCX). 
 

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:

1. https://finance.yahoo.com/news/medicus-pharma-reports-positive-phase-123000455.html
2. https://finance.yahoo.com/news/medicus-pharma-provides-interpretation-positive-113000858.html
3. https://finance.yahoo.com/news/medicus-pharma-announces-skinject-phase-113000627.html
4. https://medicuspharma.com/media/
5. https://medicuspharma.com/
6. https://finance.yahoo.com/quote/MDCX/ 
7. https://finance.yahoo.com/quote/MDCX/analyst-insights/

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 03/25/2026 and ending on 03/26/2026 (the “Campaign”) to publicly disseminate information about Medicus Pharma Ltd. (MDCX:US). Momentum Media LLC has been compensated $7,500 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.